The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).
 
Stephen Chia
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)
 
Andrew Redfern
Honoraria - Astellas Oncology; AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer
Consulting or Advisory Role - Astellas Oncology; AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer
 
Jean-Pierre Ayoub
Honoraria - AstraZeneca; Daiichi-Sankyo; Gilead Sciences; Knight Therapeutics; Lilly; Merck; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca Canada; Daiichi-Sankyo; Gilead Sciences; Knight Therapeutics; Lilly; Merck; Novartis; Pfizer
Speakers' Bureau - AstraZeneca Canada; Daiichi-Sankyo; Daiichi-Sankyo; Knight Therapeutics; Merck; Pfizer
Research Funding - AstraZeneca Canada (Inst); Daiichi-Sankyo (Inst)
Travel, Accommodations, Expenses - Knight Therapeutics
 
Haji Chalchal
No Relationships to Disclose
 
Daniel Rayson
Honoraria - Advanced Accelerator Applications; Ipsen; Pfizer
Consulting or Advisory Role - AstraZeneca Canada; Gilead Canada; Ipsen; Lilly; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche Canada
Research Funding - Gilead Sciences (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Moira Rushton
Speakers' Bureau - AstraZeneca; Gilead Sciences; Lilly
Travel, Accommodations, Expenses - Pfizer; Pfizer
 
Christine Desbiens
No Relationships to Disclose
 
Dhanusha Sabanathan
Speakers' Bureau - AstraZeneca; Lilly
Research Funding - DualityBio (Inst); MSD Oncology (Inst)
 
Jacques Raphael
Honoraria - Roche
Consulting or Advisory Role - AstraZeneca Canada; Lilly; Merck; Novartis
 
Angela Chan
Honoraria - AstraZeneca; Eisai; Merck; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; BMS GmbH & Co. KG; Gilead Sciences; Lilly; Merck; Novartis; Pfizer; Roche
 
Jessica Singh
No Relationships to Disclose
 
Christine Simmons
No Relationships to Disclose
 
Nicholas Zdenkowski
Honoraria - AstraZeneca; Eisai; Gilead Sciences; Lilly; Menarini; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; MSD; Novartis; Roche
Research Funding - Lilly (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Lilly; Novartis; Pfizer; Roche
 
Sheridan Wilson
Consulting or Advisory Role - AstraZeneca; MSD
Travel, Accommodations, Expenses - AstraZeneca; MSD
 
Danielle Rodin
Stock and Other Ownership Interests - Need
Consulting or Advisory Role - Need
 
David Cescon
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; GenomeRx; Gilead Sciences; GlaxoSmithKline; INFLEX; Lilly; Merck; Novartis; Pfizer; Roche/Genentech; SAGA Diagnostics
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Guardant Health (Inst); Inivata (Inst); Knight Therapeutics (Inst); Merck (Inst); Pfizer (Inst); ProteinQure (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene.
Expert Testimony - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Inivata/NeoGenomics
 
Frauke Schimmoller
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Lisa Gallinaro
No Relationships to Disclose
 
Bingshu Chen
No Relationships to Disclose
 
Wendy Parulekar
No Relationships to Disclose